Total submissions: 9
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000493672 | SCV000110073 | pathogenic | not provided | 2013-07-16 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000493672 | SCV000582974 | pathogenic | not provided | 2023-06-09 | criteria provided, single submitter | clinical testing | Identified in an individual with galactosemia who harbored a second variant in the GALT gene. This individual had >5% residual enzyme activity in erythrocytes and a Duarte-like isoelectric focusing banding pattern (Berry et al., 2000); Considered a milder GALT variant (Korner et al., 2019); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 25087612, 30718057, 15633893, 30808388, 31194895, 10408771, 20008339, 23690308, 10960497, 17876724, 29350350, 11261429, 10384398, 31194252, 34426522, 35677809) |
ARUP Laboratories, |
RCV000493672 | SCV000885498 | likely pathogenic | not provided | 2017-08-01 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000078235 | SCV000931179 | pathogenic | Deficiency of UDPglucose-hexose-1-phosphate uridylyltransferase | 2024-01-08 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with cysteine, which is neutral and slightly polar, at codon 258 of the GALT protein (p.Arg258Cys). This variant is present in population databases (rs368166217, gnomAD 0.006%). This missense change has been observed in individual(s) with clinical features of galactosemia (PMID: 10960497, 30718057; Invitae). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 92522). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt GALT protein function with a positive predictive value of 95%. For these reasons, this variant has been classified as Pathogenic. |
Baylor Genetics | RCV000078235 | SCV004198490 | pathogenic | Deficiency of UDPglucose-hexose-1-phosphate uridylyltransferase | 2024-03-30 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV000493672 | SCV004226597 | likely pathogenic | not provided | 2023-03-13 | criteria provided, single submitter | clinical testing | PP3, PP4, PM2, PM3, PS4_moderate |
Counsyl | RCV000078235 | SCV000800530 | likely pathogenic | Deficiency of UDPglucose-hexose-1-phosphate uridylyltransferase | 2019-03-13 | no assertion criteria provided | clinical testing | |
Biochemical Molecular Genetic Laboratory, |
RCV000078235 | SCV001469241 | likely pathogenic | Deficiency of UDPglucose-hexose-1-phosphate uridylyltransferase | 2020-10-11 | no assertion criteria provided | clinical testing | |
Revvity Omics, |
RCV000078235 | SCV003808590 | uncertain significance | Deficiency of UDPglucose-hexose-1-phosphate uridylyltransferase | 2021-04-09 | flagged submission | clinical testing |